A study from Norway on whether switching stable patients with rheumatoid arthritis (RA) treated with Remicade® to a biosimilar has revealed that outcomes were no different.
A study from Norway on whether switching stable patients with rheumatoid arthritis (RA) treated with Remicade® to a biosimilar has revealed that outcomes were no different.
The results of the NOR-SWITCH trial were announced at the United European Gastroenterology Week in Vienna, Austria, on October 18. This investigation was designed to determine how switching to Celltrion’s biosimilar (marketed as Remsima® in Europe and soon to be marketed as Inflectra® in the US) would affect patient status. This 2-year, post marketing study was designed to demonstrate noninferiority (not superiority) of Remsima to Remicade.
The approximately 500 patients entering the trial had to be receiving a stable dose of infliximab for at least 6 months at baseline. In this controlled study, half of the patients were switched to Remsima treatment. The results indicated no clinically meaningful difference in safety or efficacy. Although this trial was not designed to demonstrate the possible effects of switching back to the original product, it does bolster the case that in patients with RA, switching from Remicade to the biosimilar poses little risk.
What of switching these products in patients with other approved indications?
More data are needed to determine the effectiveness and safety of this option. In one study conducted by Celltrion’s marketing partner Pfizer, 3300 patients are being recruited to determine how often patients with inflammatory bowel disease switch from one anti-TNF to another. That study is due to end in June 2019. Will NOR-SWITCH spur US payers to encourage physicians to switch treatments, once Inflectra is launched in late November? It does offer a bit of insulation for proponents, but (1) only for Inflectra/Remsima—Remicade switches in RA not for other indications, and (2) these study results do not apply to other anti-TNFs.
However, Sandoz utilized a multiple-switching study design in one of the studies (Study 302) to support FDA approval of its etanercept biosimilar Erelzi™. In this study of plaque psoriasis, a subgroup of patients were switched between the originator product and Erelzi at weeks 12, 18, and 24, without negative effects.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.